Signifor (pasireotide)
- Region
- 🇪🇺 EU
- Active substance
- pasireotide
- Company
- Recordati Rare Diseases
- Status
- Authorised
- Therapeutic area
- Acromegaly; Pituitary ACTH Hypersecretion
- EU approval
- Tue 24 Apr 2012
- Application
- EMEA/H/C/002052
- ATC
- H01CB05
- Official record
- www.ema.europa.eu
Indication
Signifor is indicated for the treatment of adult patients with Cushing’s disease for whom surgery is not an option or for whom surgery has failed. Signifor is indicated for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue.
Regulatory milestones
No milestones recorded in the last year.
Follow Signifor
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.